Literature DB >> 17152016

Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women.

Tomasz Laskus1, Eva A Operskalski, Marek Radkowski, Jeffrey Wilkinson, Wendy J Mack, Marina deGiacomo, Lena Al-Harthi, Zhi Chen, Jiaao Xu, Andrea Kovacs.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) has been reported to replicate in peripheral blood mononuclear cells (PBMCs), particularly in patients coinfected with HCV and human immunodeficiency virus (HIV). However, there are limited data regarding the prevalence of and the factors associated with extrahepatic replication.
METHODS: The presence of negative-strand HCV RNA in PBMCs was evaluated by a strand-specific assay for 144 anti-HCV-positive/HIV-infected women enrolled in the Women's Interagency HIV Study. One to 5 PBMC samples obtained from each woman were tested. Multivariate analyses were used to assess for associations with the clinical and demographic characteristics of the women.
RESULTS: Negative-strand HCV RNA was detected in 78 (25%) of 315 specimens, and, for 61 women (42%), > or = 1 specimen was found to have positive results. The presence of negative-strand HCV RNA in PBMCs was significantly positively associated with an HCV RNA plasma level of > or = 6.75 log copies/mL (P=.04) and consumption of > or = 7 alcoholic drinks per week (P=.02). It was also negatively associated with injection drug use occurring in the past 6 months (P=.03). A negative association with a CD4+ CD38+ DR+ cell percentage of > 10% and a positive association with acquired immunodeficiency syndrome were borderline significant (P=.05).
CONCLUSIONS: HCV replication in PBMCs is common among HIV-coinfected women and appears to be a dynamic process related to lifestyle, virologic, and immunologic factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17152016      PMCID: PMC3319123          DOI: 10.1086/509897

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication.

Authors:  T Laskus; M Radkowski; L F Wang; M Nowicki; J Rakela
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  Alcohol, host defence and society.

Authors:  Steve Nelson; Jay K Kolls
Journal:  Nat Rev Immunol       Date:  2002-03       Impact factor: 53.106

3.  Clinical and therapeutic implications of hepatitis C virus compartmentalization.

Authors:  Gaëtana Di Liberto; Anne-Marie Roque-Afonso; Rachid Kara; Delphine Ducoulombier; Guillaume Fallot; Didier Samuel; Cyrille Feray
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

4.  Relation between HIV-1 and hepatitis C viral load in patients with hemophilia.

Authors:  E S Daar; H Lynn; S Donfield; E Gomperts; M W Hilgartner; W K Hoots; D Chernoff; S Arkin; W Y Wong; C A Winkler
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

5.  Comparative analysis of translation efficiencies of hepatitis C virus 5' untranslated regions among intraindividual quasispecies present in chronic infection: opposite behaviors depending on cell type.

Authors:  J Laporte; I Malet; T Andrieu; V Thibault; J J Toulme; C Wychowski; J M Pawlotsky; J M Huraux; H Agut; A Cahour
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Cell type-specific enhancement of hepatitis C virus internal ribosome entry site-directed translation due to 5' nontranslated region substitutions selected during passage of virus in lymphoblastoid cells.

Authors:  H Lerat; Y K Shimizu; S M Lemon
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid.

Authors:  Tomasz Laskus; Marek Radkowski; Agnieszka Bednarska; Jeffrey Wilkinson; Debra Adair; Marek Nowicki; Georgia B Nikolopoulou; Hugo Vargas; Jorge Rakela
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells.

Authors:  Massimo Resti; Chiara Azzari; Maria Moriondo; Letizia Betti; Idanna Sforzi; Elio Novembre; Alberto Vierucci
Journal:  Clin Infect Dis       Date:  2002-07-01       Impact factor: 9.079

9.  Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells.

Authors:  Julien Laporte; Christine Bain; Patrick Maurel; Genevieve Inchauspe; Henri Agut; Annie Cahour
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

10.  Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain.

Authors:  T Laskus; L F Wang; M Radkowski; H Vargas; M Nowicki; J Wilkinson; J Rakela
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

View more
  23 in total

1.  Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.

Authors:  Naga Suresh Veerapu; Sukanya Raghuraman; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

2.  Viral RNA but no evidence of replication can be detected in the peripheral blood mononuclear cells of hepatitis E virus-infected patients.

Authors:  S K Ippagunta; S Naik; S Jameel; K N S Ramana; R Aggarwal
Journal:  J Viral Hepat       Date:  2010-07-26       Impact factor: 3.728

3.  Hepatitis C virus and peripheral blood mononuclear cell reservoirs Patricia Baré.

Authors:  Patricia Baré
Journal:  World J Hepatol       Date:  2009-10-31

4.  Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus.

Authors:  Andrea Kovacs; Roksana Karim; Wendy J Mack; Jiaao Xu; Zhi Chen; Eva Operskalski; Toni Frederick; Alan Landay; John Voris; La Shonda Spencer; Mary A Young; Phyllis C Tien; Michael Augenbraun; Howard D Strickler; Lena Al-Harthi
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

5.  Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection.

Authors:  Farah Bokharaei Salim; Hossein Keyvani; Afsaneh Amiri; Fatemeh Jahanbakhsh Sefidi; Ramin Shakeri; Farhad Zamani
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

6.  Analysis of the 5'UTR of HCV genotype 3 grown in vitro in human B cells, T cells, and macrophages.

Authors:  Dennis Revie; Michael O Alberti; John G Prichard; Ann S Kelley; S Zaki Salahuddin
Journal:  Virol J       Date:  2010-07-13       Impact factor: 4.099

7.  Activation-induced cytidine deaminase in B cells of hepatits C virus-related cryoglobulinaemic vasculitis.

Authors:  S Russi; F Dammacco; S Sansonno; F Pavone; D Sansonno
Journal:  Clin Exp Immunol       Date:  2015-09-17       Impact factor: 4.330

8.  CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus.

Authors:  Andrea Kovacs; Lena Al-Harthi; Shawna Christensen; Wendy Mack; Mardge Cohen; Alan Landay
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

Review 9.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  HCV enters the twenty-first century.

Authors:  Indira Brar; Dwayne Baxa; Norman Markowitz
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.